Pediatric Pharmacy Association -- Advocacy. Community. Outreach. Partnership.

The mission of the Pediatric Pharmacy Association is to improve the lives of children and to advocate for safe and effective medication use in children. PPA advances its mission through grassroots advocacy (encouraging members to get engaged in legislative advocacy) and by promoting awareness of optimal medication therapy with all health care professionals by coordinating an effective communication network.

Major Advocacy Milestones: 

On October 27, 1997, Mr. Dave Grinder (founding Board member) represented PPA, then PPAG, during the FDA public hearing regarding the Food and Drug Administration Modernization Act (FDAMA), which was the first piece of legislation which established incentives for pediatric drug development. Mr. Grinder presented in support of the legislation which established regulation and incentives for manufacturers to assess the safety and effectiveness of new drugs and biological products in children.

In 2014 PPA, then PPAG, advocated for the appointment of Kathy Pham, PharmD to the FDA Pharmacy Compounding Advisory Committee as the Pediatric Clinical Pharmacy Expert.

In 2015 PPA, then PPAG, joined the Patient Access to Pharmacists' Care Coalition (PAPCC

In 2017 PPA, then PPAG, entered into a collaborative agreement with the American Academy of Pediatrics (AAP), which established a permanent liaison position in the AAP Section for Advancement in Therapeutics and Technology (SOATT) and the Section for Clinical Pharmacology and Therapeutics (SOCPT).


There are various ways we accomplish our advocacy mission:

Grassroots Action: PPA promotes a grassroots approach to promoting pediatric-friendly legislation in the US Congress. We have encouraged our members to support the following federal level laws and regulations:

  1. The Pharmaceutical Quality, Security, and Accountability Act (S. 959)
  2. Food and Drug Administration Safety and Innovation Act (FDASIA)  
  3. Legislation signed in 2012 to permanently reauthorize the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) [More info]
  4. Drug Shortages Prevention Act
  5. Preserving Access to Life Saving Medications Act
  6. The Federal 340B Drug Pricing Program
  7. SCHIP: State Children's Health Insurance Program

Partnerships. PPA promotes pediatric patient safety by partnering and collaborating with other non-profit organizations, professional associations, and governmental agencies. 

American Academy of Pediatrics
International Campaign for Better Medicine
World Health Organization (WHO) "Make Medicine Children's Size" Campaign

Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee  
Patient Access to Pharmacists’ Care Coalition (PAPCC) 

Outreach Programs. PPA promotes pediatric patient safety by providing quality information to patients, parents, and the general public. a site for parents and kids!

Special Interest Groups. Unlike anything available to pediatric pharmacists today, our SIGs offer you a chance to communicate to a highly specialized audience of your choosing. Go to your MyPPAG page for more information

The Journal of Pediatric Pharmacology and Therapeutics. The JPPT is a peer-reviewed clinical medical journal dedicated to the dissemination of information regarding the safe and effective use of medications in neonates, infants, children, and adolescents. By contributing to the medical literature the JPPT plays a vital role in advancing PPA's advocacy as well as educational missions.

The Journal of Pediatric Pharmacology and Therapeutics website

Position statements. PPA offers therapeutic position statements that respond to specific therapeutic issues. These statements are thorough, evidence-based recommendations of drug use. PPAG also offers position statements on public policy issues that are directed to health care professionals, public officials, and the general public.

PPA Position Statements page